Black kidney transplant recipients have higher prevalences of cardiovascular disease (CVD) risk factors and less intensive risk factor control than White kidney transplant recipients. Our objective was to evaluate racial disparities in receipt of statins and aspirin for secondary CVD prevention among kidney transplant recipients in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) trial.Black kidney transplant recipients have higher prevalences of cardiovascular disease (CVD) risk factors and less intensive risk factor control than White kidney transplant recipients. We conducted this study to evaluate racial disparities in receipt of statins and aspirin for secondary CVD prevention among 978 kidney transplant recipients with a history of CVD. Our study showed that Black kidney transplant recipients were less likely to receive statin and Other race kidney transplant recipients were less likely to receive aspirin for secondary CVD prevention, compared with White kidney transplant recipients.

Equitable prescription of aspirin and statin for secondary CVD prevention represents an important potential target to improve CVD care among non-White kidney transplant recipients. Kidney transplantation is the optimal treatment for individuals with kidney failure and substantially improves quality of life and decreases early mortality compared to dialysis. Cardiovascular disease (CVD) is the most common cause of death with a functioning graft among kidney transplant recipients. The high risk of CVD in kidney transplant recipients is multifactorial and includes nonmodifiable risk factors, such as age and family history, as well as modifiable risk factors, such as hypertension, dyslipidemia, obesity, diabetes mellitus, and immunosuppression. Many kidney transplant recipients do not receive guideline-concordant CVD care after transplant to manage these modifiable factors, with some studies suggesting only a small portion of prevalent kidney transplant recipients receive optimal CVD management.

visit for more articles at  Journal of Clinical & Experimental Nephrology

Kindly submit your article at https://www.imedpub.com/submissions/clinical-experimental-nephrology.html or nephrology@eclinicalsci.com 

Regards
Mishita
Jornal co-ordinator
Journal of Clinical & Experimental Nephrology